本文關(guān)鍵詞：子宮頸癌發(fā)生發(fā)展中HLA基因易感及NK細(xì)胞受體免疫應(yīng)答的作用　出處：《中國(guó)免疫學(xué)雜志》2015年11期 　論文類型：期刊論文

  更多相關(guān)文章： 子宮頸癌 人類白細(xì)胞抗原(HLA) NK 免疫應(yīng)答

【摘要】：目的:探究子宮頸癌發(fā)生發(fā)展中HLA基因易感及NK細(xì)胞受體免疫應(yīng)答的作用。方法:本研究選取2013年1月至2014年1月于我院診治,并經(jīng)病理活檢證實(shí)為子宮頸癌的患者200例作為觀察組,同時(shí),隨機(jī)選取200例健康婦女為對(duì)照組。兩組均在入院時(shí)取外周血2 ml,采集觀察組的宮頸細(xì)胞樣品用來(lái)進(jìn)行細(xì)胞學(xué)觀察和HPV的DNA探查,觀察兩組人員HPV感染率和HLA分型。結(jié)果:兩組入組人員HPV感染陽(yáng)性率分別為91%、16%,兩組比較,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者HLA-KIR*1003、HLA-KIR*14、HLA-KIR*17、HLA-KIR*02、HLA-KIR*12的分布頻率分別為41%、39%、35%、15%、53%,對(duì)照組分別為18%、15%、14%、52%、89%,兩組比較差異均具有統(tǒng)計(jì)學(xué)意義(P0.05),其中觀察組患者HLA-KIR*1003、HLA-KIR*14、HLA-KIR*17分布頻率明顯高于對(duì)照組,HLA-KIR*02、HLA-KIR*12的分布頻率明顯低于對(duì)照組。結(jié)論:在子宮頸癌發(fā)生發(fā)展的過(guò)程中,存在HLA-KIR*1003、HLA-KIR*14、HLA-KIR*17等位基因易感,而HLAKIR*02、HLA-KIR*12等位基因可減少宮頸癌的發(fā)生。
[Abstract]:Objective: to investigate the role of HLA gene susceptibility and NK cell receptor immune response in the occurrence and development of cervical cancer. Methods: from January 2013 to January 2014, the study was conducted in our hospital. 200 cases of cervical cancer confirmed by pathological biopsy as the observation group, and 200 healthy women as the control group were randomly selected. The peripheral blood of both groups were taken 2 ml on admission. Samples of cervical cells were collected from the observation group for cytological observation and DNA detection of HPV. HPV infection rate and HLA typing were observed in two groups. Results: the positive rates of HPV infection in the two groups were 91% and 16%, respectively. The difference was statistically significant (P 0.05). The distribution frequency of HLA-KIR*12 was 41% and 39%, respectively. In the control group, it was 18% and 52%, respectively. The difference between the two groups was statistically significant (P 0.05), among which HLA-KIRN 1003T HLA-KIR14 was found in the observation group. The frequency of HLA-KIR*17 distribution was significantly higher than that of control group. The distribution frequency of HLA-KIR*12 was significantly lower than that of the control group. Conclusion: during the development of cervical cancer, there is HLA-KIR1 003 HLA-KIR14. HLA-KIR*17 alleles were susceptible, while HLA-KIR12 alleles were associated with a decrease in the occurrence of cervical cancer.
【作者單位】： 廣州醫(yī)科大學(xué)附屬第三醫(yī)院生殖中心;廣州醫(yī)科大學(xué)附屬第三醫(yī)院婦科;
【基金】：廣東省醫(yī)學(xué)科學(xué)技術(shù)研究基金(WSTJJ20121108440102197212313220)資助
【分類號(hào)】：R737.33
【正文快照】： 1本文受廣東省醫(yī)學(xué)科學(xué)技術(shù)研究基金(WSTJJ20121108440102197212313220)資助。2廣州醫(yī)科大學(xué)附屬第三醫(yī)院婦科,廣州510510。子宮頸癌是較為常見的女性惡性腫瘤,其發(fā)病率僅次于乳腺癌,其中發(fā)展中國(guó)家發(fā)病率較高,有資料顯示,大于85%的子宮頸癌新發(fā)及死亡病例在發(fā)展中國(guó)家,其中印

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 劉昱;祁文娟;魏麗惠;;HPV預(yù)防性疫苗在預(yù)防子宮頸癌中的應(yīng)用進(jìn)展[J];中國(guó)婦產(chǎn)科臨床雜志;2013年04期

2 唐雋;郝飛;;HPV逃避宮頸癌宿主免疫應(yīng)答的機(jī)制[J];免疫學(xué)雜志;2011年07期

3 李華;百合尼莎·阿不都熱西提;張?zhí)K琴;古扎麗努爾·阿不力孜;;喀什維吾爾族婦女宮頸癌與HLA-DRB1*15和HLA-DRB1*04的關(guān)系[J];復(fù)旦學(xué)報(bào)(醫(yī)學(xué)版);2010年05期

4 夏小艷;瑪依努爾·尼亞孜;;HPV及HLA與宮頸癌關(guān)系研究進(jìn)展[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2010年08期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 邱翠華;朱薛艷;;中藥對(duì)甲氨蝶呤治療未破裂型異位妊娠療效的影響[J];中醫(yī)藥臨床雜志;2006年02期

2 葉紅娟;;自擬活血解毒湯保留灌腸治療慢性盆腔炎84例[J];中醫(yī)藥臨床雜志;2006年06期

3 張菁;呂秀花;韓云鵬;;益氣固沖湯治療更年期功能失調(diào)性子宮出血46例[J];中醫(yī)藥臨床雜志;2007年01期

4 李，

本文編號(hào)：1432972